mainly derived from the liver under the regulation of growth hormone (GH), but many tissues secrete IGF-I and -II and are sensitive to their autocrine actions (Humbrel, 1990) . At high concentrations, IGFs can exert acute metabolic effects via the insulin receptor, but their predominant, long-term effects are upon tissue growth and differentiation. IGF actions are modulated by a family of six specific binding proteins, the IGFBPs, which may inhibit or enhance IGF actions (Rechler, 1994) . High-affinity binding of the IGFs to the IGFBPs prevents receptor binding, thus inhibiting IGF effects; however, the mechanisms responsible for potentiation are not clear.
Overproduction of these potent growth factors has been reported in established tumours of the breast, kidney and liver (Reeve et al, 1985; Haselbacher et al, 1987; Foekens et al, 1989; Singh et al, 1990) and IGFs are implicated in tumour development (Cullen et al, 1991) . Thus, in Beckwith Weidemann syndrome, in which the IGF-II gene is effectively overexpressed, there is an excess of tumours in childhood (Weidemann, 1983; Truleau et al, 1984) . In addition, in acromegaly, in which circulating IGF levels are raised, there is an increased incidence of colonic polyps and cancers and of thyroid tumours (Ezzat, 1992; Braziley et al, 1991) .
In normal colon, IGF-II mRNA is not expressed, but in cancers it is overexpressed in one-third of cases, suggesting that autocrine IGF may be important in tumour growth (Tricoli et al, 1986) . Differences between normal and neoplastic IGFBP production have not been studied in the colon, although dysregulation of the circulating IGFBP-2/-3 ratio has been reported in those with established colonic cancer (El Atiq et al, 1994) . Expression of IGFBP mRNA in colonic cancer (mainly IGFBP-2 and -4), reflecting that seen in some established colon cell lines, has been reported, but no comparisons to normal mucosal expression have been made (Singh et al, 1995) .
Specific proteases for IGFBPs have been characterized from several tissues. Starvation induces calcium-dependent serine proteases specific for IGFBP-2, and the degraded fragments bind IGFs with much lower affinity (McCusker et al, 1991) . There are also specific proteases for IGFBP-3 that become activated under stress (Davenport et al, 1992) and during pregnancy (Guidice et al, 1990) , and again binding affinity is reduced by proteolysis. Specific IGFBP-4 proteases require IGFs for activation, and studies to date show that this proteolysis relieves the inhibitory effects of IGFBP-4 on IGF action (Cohick et al, 1993; Conover et al, 1993) . Proteolysis of IGFBP-5, which has been observed in osteoblast cells, potentiates the effects of IGF-I (Andress and Bimbaum, 1992) . The fragments have been shown to have effects independent from IGF-I (Andress et al, 1993) . Table 1 IGF and IGFBP mRNA expression determined by Northern Blot  analysis from ten paired normal and malignant colonic mucosa specimens   IGF-I IGF-II BP-1 BP-2  BP-3 BP-4 BP-5 BP-6   Normal 10  0  0  10  3  7  3  2   Cancer 10  3  0  10  5  7  3  3 2.0 kb> 2.5 kb> 2.6 kb> N C N C Figure 1 IGFBP mRNA expression by normal (N) and malignant (C) colonic mucosa was determined by Northern analysis using 32P-labelled cDNAs as probes. Representative autoradiographs of IGFBP-2 mRNA (2.0 kb), IGFBP-3 mRNA (2.5 kb) and IGFBP-4 mRNA (2.6 kb) are shown. Transcript sizes were determined by comparison to rat rRNA markers (Sigma) The aim of this study was to determine the role of the IGF axis in colonic cancer. We examined the expression of IGFs and IGFBPs in normal and cancerous colonic tissue by Northern and Western blotting. We also determined the patterns of IGFBP production by cultured normal and neoplastic epithelium obtained from patients at operation, and in addition we have measured cellular growth responses to IGF-1. Because we observed a reduction in the expression of IGFBP-2 in the cancer tissues that did not correlate with the expression of its mRNA, we examined whether there was enhanced proteolysis of IGFBPs in the tumours.
MATERIALS AND METHODS
Primary cultures of colonic epithelium Primary cultures were obtained from 10 paired normal and tumour tissues using the method described by Moyer (1983) with modifications. Cancers were all sporadic with Duke's stage B or C classification. Tissues were collected directly from the operating theatres, rapidly dissected and thoroughly washed in Hanks' balanced salt solution (HBSS). Using a blunt spatula, the epithelium was scraped from the normal mucosa and homogenized on ice using five up-down strokes in a Dounce glass tissue homogenizer. After centrifugation at 800 r.p.m. for 5 min, the cells were resuspended in 10% fetal bovine serum (FBS) (Gibco) in Dulbecco's modified Eagle medium/Ham's F12 (DMEM/F12M) 1:1 (Sigma Chemical) supplemented with antibiotics (penicillin 100 U ml-', gentamycin 100 ,ug ml-' and metronidazole 100 ,ug ml-') at 1 04 cells ml-'. Tumour tissue was finely minced with opposed scalpels, homogenized and cultured as for the normal epithelium.
Cells were cultured in serum-supplemented media for 24 h, during which time contaminating fibroblasts became adherent to the culture flasks, while the epithelial and tumour cells remained in suspension. Cells in suspension were then washed in HBSS and maintained serum free in DMEM/F12M supplemented in antibiotics. Cell viability at each stage was determined by trypan blue exlusion.
Cell morphology
Once established in serum-free conditions, cells were cytospun onto slides, fixed with acetone and stained with Giemsa and with cytokeratin 17 antibody using peroxidase-diaminobenzidine for detection. Cell type and number were determined by an independent pathologist. and Professor S Shimasaki (La Jolla) respectively. After hybridization at 650 C for 16 h, membranes were washed in solutions of SDS and standard saline citrate (SSC, 10 mm sodium citrate, 150 mm sodium chloride, pH 7.0) 0.1% SDS in 2 x SSC for 30 min at 22°C, 0.1% SDS in 0.2 x SSC for 15 min at 45°C and 0.1% SDS in 0.2 x SSC for 15-30 min at 65°C. Bands were visualized by autoradiography after exposure to Kodak AR film for 16 h to 5 days at -80°C. Figure 2 IGF-I and -11 mRNA expression in normal and malignant colonic mucosa was determined by Northern analysis using 32P-labelled cDNAs.
Protein synthesis
Representative autoradiographs of three paired tissues are shown. Transcript sizes of IGF-I mRNA (8.0 kb) and IGF-11 mRNA (6.0 kb) were determined by comparison to rat rRNA markers (TCS). Membranes were reblocked, washed in phosphate-buffered saline (PBS, 10 mM sodium phosphate, 150 mm sodium chloride, pH 7.0) for 30 min and incubated with 1:500 dilution of primary antibody for 1 h. After a second PBS wash, membranes were incubated with horseradish peroxidase-linked anti-rabbit IgG secondary antibody (1:75 000 dilution, Amersham) for 1 h. Antibody binding was visualized using the Amersham Enhanced Chemiluminesence System (ECL).
Northern blot analysis Ten paired samples of normal and neoplastic tissue were studied. Freshly collected tissues (whole bowel) were rapidly frozen in liquid nitrogen, and total RNA was extracted using the single-step method (Chomczynski and Sacchi, 1987) . RNA purity was determined by its 260:280 nm absorbance ratio and quantified by its absorbance at 260 nm. Thirty micrograms of RNA were separated on a denaturing (18.5% formaldehyde) 1% agarose gel (100 V for 3 h) and transferred by capillary action over 16 h onto nylon membranes (Zetaprobe, BioRad). Membranes were blocked for 5 min in 7% SDS in 0.5 M phosphate buffer (pH 7.2) at 65°C. 32p_ labelled cDNAs for IGF-I and II, and IGFBPs 1-6 were synthesized by random primer extension using a commercially available kit (Oligolabeling kit, Pharmacia). Template cDNAs for the IGFs and IGFBPs were kindly provided by Professor GI Bell (Chicago)
Immunohistochemistry
Ten paired samples were used. Tissue was formalin fixed, embedded in wax, sectioned and mounted. Sections were dewaxed by washing in xylene and rehydrated by sequential ethanol washes (10 min each in 100%, 90%, 80%, 60% and 50% ethanol). Endogenous peroxidase activity was inhibited by incubation with methanol/0.01% hydrogen peroxide for 30 min. Sections were blocked for 1 h at room temperature with 5% albumin. Primary antibodies to IGF-I (NIH) and -II (Gro-pep) and IGFBPs 2-4 (Upstate Biologicals) were diluted 1:500 with PBS and incubated with sections for 1 h at room temperature. Slides were thoroughly washed and secondary antibody was added for 30 min. Following a 30-min PBS wash, antibody binding was visualized using the avidin-biotin complex system (Vectastain). Sections were counterstained with Meyer's haematoxylin. Immunoreactivity was independently scored.
IGFBP protease activity
Fifty-milligram samples of frozen tissue (normal and tumours) were rapidly homogenized in HBSS in a Class II containment cabinet using a mechanical homogenizer and were analysed for IGFBP content and protease activity. IGFBP content of 5-ml homogenates were determined by Western ligand analysis. Proteins were precipitated under three volumes of ethanol at -20°C for 2 h and pelleted by centrifugation at 2000 r.p.m. for 30 min. The IGFBP content was determined by Western ligand analysis as described above. IGFBP protease activity in these homogenates was determined by adding known IGFBPs to these homogenates and following their degradation. We have previously found that two human cell lines derived from pancreatic cancer produce large amounts of IGFBPs. BxPc-3 and SUIT-2 cellconditioned medium were used as the source of IGFBP-2, -4 and IGFBP-3, -4 respectively. IGFBPs were derived from single cultures of these serum-free cell lines to ensure consistency of binding protein type and concentration. Five-millilitre aliquots from each homogenized sample were incubated with IGFBP-2 and -4 or IGFBP-3 and -4 for 1 h at 37°C. Control incubations of BxPc-3 and SUIT-2 cell-conditioned medium without homogenate were run in parallel to control for endogenous proteolysis of the IGFBPs. The effect of heating each sample to 100°C for 5 min before IGFBP addition was also determined. Following co-incubations, IGFBPs were precipitated under three volumes of ethanol and identified by Western ligand analysis. RESULTS IGFBP mRNA expression in normal and cancer tissues Figure 3 Purified normal (A) and neoplastic (B) colonocytes were fixed and stained after 24 h in culture. Cell type was determined by morphology after staining with Giemsa stain (left) with anti-cytokeratin 17 antibody (right) (2.0 kb), IGFBP-3 (2.5 kb) and IGFBP-4 (2.6 kb) are shown in Figure 1 . IGFBP-2 mRNA was uniformly expressed by normal and cancer tissues (1O out of 10). IGFBP-3 mRNA was detected in 3 out of 10 normal colonic epithelium specimens and in 5 out of 10 cancer specimens. IGFBP-4 mRNA was detected in 7 out of 10 normal and 7 out of 10 cancer specimens. IGFBP-5 mRNA was expressed in 3 out of 10 normal and 3 out of 10 cancer specimens and IGFBP-6 mRNA by 2 out of 10 normal and 3 out of 10 cancer tissues. IGFBP-l mRNA was not detected in any sample.
IGF-I and -11 mRNA expression Figure 2 shows IGF-I and -II mRNA expression by Northern analysis in three paired samples of normal and cancer tissue. Ten paired samples were analysed in total and the data are shown in Table 1 . All normal and colonic cancer tissues expressed IGF-I mRNA. The absolute amount of 8.0-kB IGF-I mRNA relative to rRNA varied considerably both between the normal tissues and their tumour counterparts, and no consistent quantitative differences were observed. In Figure 2 , the cancer tissue shown in lane 3, which shows strong IGF-II mRNA labelling, was also positive for IGF-I on longer exposure. IGF-II mRNA was expressed by 3 out of 10 cancers but was not detected in normal tissue.
Immunohistochemistry
The results of immunostaining for the IGFs and IGFBPs are shown in Table 2 . No IGF-I or-II could be detected in any sample. This may be because of the loss of IGFs during tissue fixation or because of the loss of immunoreactivity. Staining for IGFBP-2 was observed in 7 out of 10 normal samples and in 2 out of 10 cancer samples. Positive IGFBP-3 staining was seen in 7 out of 10 normal and 7 out of 10 cancer specimens, and IGFBP-4 staining was seen in 6 out of 10 normal and 5 out of 10 cancer samples. In all cases, immunoreactivity was confined to the epithelial and cancer cells.
Primary culture characterization Purified colonocytes were confirmed as normal epithelial or tumour cells by Giemsa and cytokeratin 17 staining (Figure 3 ). Less than 5% were contaminating fibroblasts. Maintenance of differentiation was confirmed by induction of mRNA for 24-hydroxylase with vitamin D3 treatment (Kane et al, 1994) .
Protein synthesis and DNA synthesis
[35S]methionine incorporation of paired normal and cancer colonocytes cultured in serum-free medium after stimulation with IGF-I (30 ng ml-1) for 48 h was determined. The experiment was repeated four times with triplicate samples. Sodium azide (0.1%), a cytotoxic agent, was added to some cultures to control for nonspecific radioactivity. The data are shown in Table 3 . We have not pooled the data from the experiments because of the inherent variability of primary cultures. In the normal cells, there was no significant increase in incorporation after treatment with 30 ng ml-' IGF-I in any of the experiments, whereas the incorporation of [3H]thymidine was significantly increased by 30 ng ml-' IGF-I in all experiments with the colonocytes derived from the tumours.
IGFBP secreted from cells in culture Westem blots Figure 4 shows the results of Westem blotting for IGFBP-2 in four paired samples from normal and cancer colonocytes and Table 4 summarizes the data obtained with IGFBP-2, -3 and -4 antisera British Journal of Cancer (1997) 76(1) (Kane et al, 1994) , in response to vitamin D, indicated that cells remained functional. We were able to maintain viable cells in serum-free media, which allowed analyses of secreted proteins. (Guo et al, 1992) .
All tissues, neoplastic or not, expressed IGF-I mRNA but no normal tissue expressed IGF-II mRNA. In 3 of 10 tumours, IGF-II mRNA was detected, consistent with the study of Tricoli et al (1986) . As IGF-II mRNA synthesis has been shown to correlate with protein synthesis in colonic cancer (Lambert et al, 1990) , it is possible that IGF-II is acting as an autonomous growth factor in a significant proportion of colonic cancer cases. Our failure to detect IGFs on the tissue sections may be loss of these small polypeptides during fixing and washing or because of their proteolysis.
IGFBP mRNA expression did not differ materially between normal and malignant colonic tissue, IGFBP-2 being present in all samples, IGFBP-4 being detected frequently and IGFBP-3, -5 and -6 less often. Although these assessments were not quantitative, the universal detection of IGFBP-2 mRNA confirms the integrity of the mRNA, and the negative data with some samples are thus likely to be real. Low levels of mRNA may however not be detected.
Western analyses using the primary cultures of colonocytes showed that IGFBPs were less often detectable than their corresponding mRNAs in the tissue. Western ligand blots showed fewer positive samples than the antibody blots, although the antibody blots showed ostensibly intact IGFBP-2. Whether there is limited proteolysis occurring in a step-wise fashion from the N-or Cterminus of the IGFBP, which renders it incapable of binding IGF on a ligand blot, is a possibility. Immunoreactive IGFBP-2 was consistently detected in the conditioned medium and tissue sections from normal colonic epithelial cells but not in those from cancers. As the cancer tissue expresses the mRNA for IGFBP-2, the loss of IGFBP-2 in the conditioned medium again implicates proteolysis.
IGFBP proteases have been detected for IGFBP-3 in prostatic cancer (Cohen et al, 1994) and IGFBP-4 in osteoblast cell systems (Lalou et al, 1994) . A serine protease that specifically degrades IGFBP-5 in fibroblasts has been reported (Nam et al, 1994) . In pregnancy, a serum protease exists that degrades IGFBP-3 (Giudice et al, 1990) . In all of these conditions, IGFBP degradation, specific or general, resulted in enhanced IGF activity, and dysregulation of this process may promote autonomous growth. There have been no reports of the presence of IGFBP proteases or their inhibitors in the colon.
In our degradation studies, we used native glycosylated human IGFBPs as substrates rather than recombinant, radiolabelled IGFBPs because of the possibility that specific IGFBP proteases may require IGFBPs of the same species of origin and of native conformation. IGFBP-4 is degraded by both the normal and the cancer tissue extracts. There is however no difference between the normal and the cancer tissue in this regard, and in the immunostaining experiments there is no marked difference in the expression of IGFBP-4 in vivo Our consistent detection of mRNA for IGFBP-3 and the identification of immunoreactive IGFBP-3 in tissue sections, but not in cell-conditioned media, may indicate that this IGFBP-3 is made locally by other cell types in the tissue.
rapidly. The immunostaining data would argue against the latter interpretation because most normal and cancer tissues express immunoreactive IGFBP-3.
In contrast to the data with IGFBP-3 and IGFBP-4, IGFBP-2 was degraded by extracts of colonic tumour tissue but not normal tissue. Our data with IGFBP-2 imply that in the normal tissue IGFBP-2 is protected or that in the tumour tissues there is a protease specific for IGFBP-2. We have reported elsewhere (Michell et al, 1995) that IGFBP-2 can inhibit IGF-I-induced cell growth and loss of this IGFBP could give cancerous cells a growth advantage. The loss of IGFBP-2 in the cancer tissues was also seen in the immunostained sections from patients for whom 7 out of 10 normal samples showed positive immunoreactivity compared with 2 out of 10 from the colon tumours. These data indicate that IGFBP-2 is degraded by the tumours in vivo.
Our findings of decreased IGFBP-2 secretion by cancers contrasts with the suggestion that serum levels of IGFBP-2 may be elevated in cancer patients (El Atiq et al, 1994) . However, circulating IGFBPs, like circulating IGFs, are likely to originate from the liver, and they may not be important in modulating the autocrine effects of IGFs at the tissue.
We conclude that malignant colonocytes both respond to IGFs and produce IGFBPs. Resistance of normal colonocytes to IGFs may be due to the secretion of inhibitory IGFBP-2, which appears to be protected from proteolysis. IGFBP-2 is degraded by cancer cells, which may confer a growth advantage.
